vigabatrin
Also known as CPP-109, MDL-71754, Sabril®, gamma-vinyl-gamma-aminobutyric acid, gamma-vinyl GABA, GVG, 4-Amino-5-hexenoic acid, gamma-Vinyl-gamma-aminobutyric acid
Vigabatrin, sold under the brand name Vigafyde among others, is a medication used in the management and treatment of infantile spasms and refractory complex partial seizures.
Key facts
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 470630102
- Drug.image
- Vigabatrin.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200px
- Drug.image2
- Vigabatrin ball-and-stick.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 200px
- Drug.tradename
- Vigafyde, Sabril, others
- Drug.MedlinePlus
- a610016
- Drug.DailyMedID
- Vigabatrin
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
Article
22 sectionsContents
- Medical uses
- Epilepsy
- Others
- Adverse effects
- Central nervous system
- Gastrointestinal
- Body as a whole
- Teratogenicity
- Sensory
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- Society and culture
- Legal status
- Brand Names
- Research
- Solution versus powder formulation
- The PREVeNT Trial
- EPISTOP Trial
- References
Vigabatrin, sold under the brand name Vigafyde among others, is a medication used in the management and treatment of infantile spasms and refractory complex partial seizures.
It works by inhibiting the breakdown of γ-aminobutyric acid (GABA). It is also known as γ-vinyl-GABA, and is a structural analogue of GABA, but does not bind to GABA receptors.